Based on the Akebia Ther stock forecast from 1 analysts, the average analyst target price for Akebia Ther is USD 7.50 over the next 12 months. Akebia Ther’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Akebia Ther is Bearish, which is based on 2 positive signals and 5 negative signals. At the last closing, Akebia Ther’s stock price was USD 1.86. Akebia Ther’s stock price has changed by -2.11% over the past week, -9.27% over the past month and +25.68% over the last year.
No recent analyst target price found for Akebia Ther
No recent average analyst rating found for Akebia Ther
Company Overview Akebia Ther
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts. Read Less
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl...Read More
Frequently Asked Questions About Akebia Ther (AKBA) Stock
Based on ratings from 1 analysts Akebia Ther's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 3 buy, sell and hold ratings.
Unfortunately we do not have enough data on AKBA's stock to indicate if its a good dividend stock.
Based on targets from 1 analysts, the average taret price for AKBA is USD 7.50 over the next 12 months. The maximum analyst target price is USD 7.5 while the minimum anlayst target price is USD 7.5.
Unfortunately we do not have enough data on AKBA's stock to indicate if its overvalued.
The last closing price of AKBA's stock was USD 1.86.
The most recent market capitalization for AKBA is USD 0.43B.
Based on targets from 1 analysts, the average taret price for AKBA is projected at USD 7.50 over the next 12 months.
This means that AKBA's stock price may go up by +303.23% over the next 12 months.
We can't find any ETFs which contains Akebia Ther's stock.
As per our most recent records Akebia Ther has 167 Employees.
Akebia Ther's registered address is 245 First Street, Cambridge, MA, United States, 02142.
You can get more information about it from Akebia Ther's website at https://www.akebia.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Low Revenue Growth
This stock has shown below median revenue growth in the previous 5 years compared to its sector
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Akebia Ther (AKBA) Stock
Based on ratings from 1 analysts Akebia Ther's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 3 buy, sell and hold ratings.
Unfortunately we do not have enough data on AKBA's stock to indicate if its a good dividend stock.
Based on targets from 1 analysts, the average taret price for AKBA is USD 7.50 over the next 12 months. The maximum analyst target price is USD 7.5 while the minimum anlayst target price is USD 7.5.
Unfortunately we do not have enough data on AKBA's stock to indicate if its overvalued.
The last closing price of AKBA's stock was USD 1.86.
The most recent market capitalization for AKBA is USD 0.43B.
Based on targets from 1 analysts, the average taret price for AKBA is projected at USD 7.50 over the next 12 months.
This means that AKBA's stock price may go up by +303.23% over the next 12 months.
We can't find any ETFs which contains Akebia Ther's stock.
As per our most recent records Akebia Ther has 167 Employees.
Akebia Ther's registered address is 245 First Street, Cambridge, MA, United States, 02142.
You can get more information about it from Akebia Ther's website at https://www.akebia.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for AKBA !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
